Long-term outcomes with pimavanserin for psychosis in clinical practice

INTRODUCTION: Pimavanserin is the only medication FDA-approved for the treatment of Parkinson disease (PD) psychosis (PDP), but reports of long-term, real-world clinical experience are lacking. METHODS: A retrospective chart review of all patients treated with pimavanserin was conducted at our large...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbar, Umer, Friedman, Joseph H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036130/
https://www.ncbi.nlm.nih.gov/pubmed/35479873
http://dx.doi.org/10.1016/j.prdoa.2022.100143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036130/
https://www.ncbi.nlm.nih.gov/pubmed/35479873
http://dx.doi.org/10.1016/j.prdoa.2022.100143

Ejemplares similares